Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 47(2); 2015 > Article
Case Report Primary Histiocytic Sarcoma of the Central Nervous System
Hoonsub So, MD1, Sun A Kim, MD2, Dok Hyun Yoon, MD, PhD3, Shin Kwang Khang, MD, PhD2, Jihye Hwang, MD4, Chong Hyun Suh, MD5, Cheolwon Suh, MD, PhD3,
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015;47(2):322-328.
DOI: https://doi.org/10.4143/crt.2013.163
Published online: August 29, 2014

1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Department of Pathology Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

4Departmens of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

5Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence: Cheolwon Suh, MD, PhD  Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea 
Tel: 82-2-3010-3209 Fax: 82-2-3010-6961 E-mail: csuh@amc.seoul.kr
• Received: August 28, 2013   • Accepted: October 15, 2013

Copyright © 2015 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 16,428 Views
  • 201 Download
  • 18 Web of Science
  • 18 Crossref
  • 22 Scopus
prev next
  • Histiocytic sarcoma is a type of lymphoma that rarely involves the central nervous system (CNS). Its rarity can easily lead to a misdiagnosis. We describe a patient with primary CNS histocytic sarcoma involving the cerebral hemisphere and spinal cord, who had been initially misdiagnosed as demyelinating disease. Two biopsies were necessary before a correct diagnosis was made. A histologic examination showed bizarre shaped histiocytes with larger nuclei and nuclear atypia. The cells were positive for CD68, CD163, and S-100 protein. As a resection was not feasible due to multifocality, he was treated with highdose methotrexate, but showed no response. As a result, he was switched to high dose cytarabine; but again, showed no response. The patient died 2 months from the start of chemotherapy and 8 months from the onset of symptoms. Since few patients with this condition have been described and histopathology is difficult to diagnose, suspicion of the disease is essential.
Histiocytes are cells fully differentiated from the monocyte/macrophage lineage and Langerhans/dendritic cells. Histiocytic and dendritic cell neoplasms are classified together by the World Health Organization, based on the cell function, rather than histogenesis. Histiocytic sarcomas are malignant proliferations of non-Langerhans histiocytes, excluding acute monocytic leukemias and associated neoplasms [1].
The pathogenesis of histiocytic sarcoma remains unclear. Furthermore, it can occur at any age, from infancy to adulthood, with several series reporting a greater predilection in males than in females. The most frequently involved organs are the skin, lymph nodes, and intestinal tract; however, it can also involve other organs. Clinical manifestations depend on the involved organs and can range from an asymptomatic single mass to systemic symptoms, including fever and weight loss.
To date, only tens of cases have been reported to involve the central nervous system (CNS) (Table 1) [2-14]. These patients usually have an extremely poor prognosis. We describe here a patient with primary CNS histiocytic sarcoma, with the involvement of multiple areas within the cerebral hemisphere and spinal cord, who was initially misdiagnosed as having demyelinating disease.
A 59-year-old man was presented with progressive right side weakness and numbness in the left leg for 2 months. The deep tendon reflex on his right side was hyperactive, but there was no evidence of dysarthria, dysphagia, or defecation problems. His past history includes hypertension, diabetes mellitus, and coronary artery disease.
Laboratory findings were unremarkable. Blood glucose concentration was under control, and blood pressure was maintained around 140/90 mm Hg.
Magnetic resonance imaging (MRI) revealed multiple ill-defined T2 high signal intensity lesions in his brain and spinal cord. Brain lesions involved the left parieto-occipital periventricular area, extending to the right side through the splenium of corpus callosum, and both frontal lobes. These lesions showed high signal intensity on T2-weighted images, subtle increases in signal intensity on diffusion-weighted images, and patchy irregular enhancement following contrast injection (Fig. 1A and B). The lesions in the spinal cord had smooth margins and were distributed from the lower level of C3 to the upper level of T5, resulting in mild cord enlargement (Fig. 1C). T1-weighted enhanced sagittal image showed patchy enhancement in the corresponding spinal cord (Fig. 1D). Angiography showed no evidence of vascular abnormalities. The preliminary diagnosis was lymphoma or demyelinating disease.
A sample of cerebrospinal fluid (CSF) was obtained for cytologic diagnosis. Giemsa staining revealed a few large cells intermixed with mature lymphocytes. The large cells had abundant cytoplasm and round to oval large nuclei with coarse chromatin, morphologically consistent with histiocytes (Fig. 2A).
Large cells with abundant cytoplasm, similar to the cells in CSF smear, were mostly present in a stereotactic biopsy of the lesion in the left parieto-occipital area (Fig. 2B). Morphologically, these cells had characteristics of histiocytes, a finding supported by their positivity for CD68. Blood vessels within the lesion were surrounded by mature, normal-looking lymphocytes. Although a few bizarre giant cells were present (Fig. 2C), they appeared similar to adjacent histiocytes, except for their size, and were positive for CD68 (Fig. 2D). Due to the abundance of histiocyte infiltration in the absence of necrosis, hemorrhage, and neutrophil infiltration, the lesions were considered to have resulted from demyelinating disease.
Based on a clinical and pathologic diagnosis of tumefactive multiple sclerosis, the patient was treated with steroid pulse therapy and plasmapheresis, and subsequently with azathioprine. However, his neurologic symptoms did not improve. A follow-up MRI, performed 3 months after the first biopsy, showed that the extent of the left paraventricular lesion had widened, and that there were new lesions in the T4-T9 and T10-T11 levels of the spinal cord.
The possibility of neoplasm was considered likely, and a second biopsy was performed at the deeper part of the adjacent lesion from the first site. Three months have passed since the first biopsy. The histologic features of the second biopsy specimen were generally the same as that of the first, showing large cells with abundant eosinophilic to amphophilic cytoplasm (Fig. 3A). The nuclei were located eccentrically and chromatin was coarsely clumped with occasional visible nucleoli. The nucleus size was larger, and nuclear atypia was more severe than in normal histiocytes. Bizarre cells, with very large hyperchromatic nuclei, were more frequent than in the first biopsy specimen. Immunohistochemistry showed that the cells, including the large bizarre cells, were positive for CD68, CD163, and S-100 proteins, which suggest their histiocytic nature. The cells were negative for glial fibrillary acid protein (GFAP) and cytomegalovirus (CMV) antigen, excluding the possibilities of glioblastoma and CMV infection, respectively (Fig. 3B-D). The diagnosis was revised to histiocytic sarcoma.
For a staging evaluation, chest and abdominal computed tomography, positron emission tomography, and bone marrow studies were performed, and there was no evidence of lymphoma involvement other than the brain and spinal cord.
The patient was treated with two courses of high dose methotrexate (MTX) as the first line of treatment. A total dose of 3,500 mg/m2 MTX was administered for 120 minutes on day 1, every 2 weeks. Leucovorin rescue was followed 24 hours after MTX administration. As the tumor did not respond to two courses of the treatment, the regimen was changed to cytarabine (Ara-C) in a dose of 3,000 mg/m2 on day 1 and 2, every 4 weeks. MRI and positron emission tomography after two courses of Ara-C showed increased tumor extent and linear enhancement of the anterior aspect of the spinal cord at the lumbar spine level, indicating disease progression. The patient died 2 months after the second biopsy, and 8 months after the onset of symptoms.
Since the first description of histiocytic sarcoma in 1970, a few cases with CNS involvement have been reported. Patients can present symptoms thatrange from a simple headache to neurologic deficits. Neurologic deficits can significantly impair a patient’s general condition, making the disease harder to manage. Histiocytic sarcomas can involve any site within the CNS, including the brain parenchyma, spinal cord, and meninges. Our patient was apparently the third to show involvement of both the brain and the intramedullary region at presentation [3,14].
A histologic diagnosis of histiocytic sarcoma requires the presence of cells with morphologic characteristics of histiocytes and an appropriate immunophenotype [1]. Morphologically, these tumors are composed of highly cellular non-cohesive proliferations of round, oval or polygonal cells with indistinct cell membranes. The cytoplasm is abundant and eosinophilic to amphophilic. The nuclei vary in size and shape, from small and round to large and irregular, which can sometimes even exhibit a lobulated shape. Very large bizarre and occasionally multinucleated cells may be observed. The tumor cells are positive for histiocyte-associated antigens, including CD68, lysozyme, HAM-56, 1-antitrypsin, α1-antichymotrypsin, and nonspecific esterase, but are negative for B cell, T cell, myeloid, follicular dendritic cell, and Langerhans cell markers (CD1a), as well as CD30.
The patient was first diagnosed with a demyelinating disease. The lesions were multifocal, involving the periventricular areas and spinal cord, and a biopsy revealed many histiocytes with inflammatory infiltrates. The small biopsy specimen contained mostly monomorphic histiocytes, with only a few large cells that were overlooked. Histiocytic sarcoma should be distinguished from demyelinating diseases, which are treated with steroids. Both diseases are characterized by abundant histiocytic infiltrates, and their differentiation is further complicated when neoplastic histiocytes are intermixed with prominent inflammatory components [9,10]. The tumor cells of histiocytic sarcoma vary in size, from 18 to 26 μm, with many larger than non-neoplastic histiocytes [1,9], and with abundant cytoplasm and large hyperchromatic nuclei. Nuclear atypia and pleomorphism with occasional large bizarre nuclei are the key features that distinguish histiocytic sarcoma from non-neoplastic histiocytic infiltration in demyelinating diseases.
Histiocytic sarcoma can be confused with other histiocytic or histiocyte-like lesions in the brain, such as Langerhans cell histiocytosis, Rosai-Dorfman disease, and juvenile xanthogranuloma [1,15]. Histiocytes in Langerhans cell histiocytosis have indented or lobulated nuclei without significant atypia, which are positive for CD1a, and are accompanied by eosinophilic infiltration. Rosai-Dorfman disease is characterized by emperipolesis and infiltration by numerous plasma cells, with histiocytes having voluminous, amphophilic cytoplasm, and round nuclei with prominent nucleoli. In juvenile xanthogranuloma, the histiocytes are often lipidized, with a few showing significant atypia [15].
Primary CNS tumors with pleomorphic or large bizarre cells can mimic histiocytic sarcoma [1]. Glioblastoma, the most common primary intraparenchymal tumor of the CNS, often has many bizarre and atypical large cells. However, these cells possess cytoplasmic processes, resulting in a fibrillary appearance in the background, which are positive for GFAP, and are negative for histiocytic markers. Pleomorphic xanthoastrocytoma is a prototype of tumors with pleoPrimary CNS tumors with pleomorphic or large bizarre cells can mimic histiocytic sarcoma [1]. Glioblastoma, the most common primary intraparenchymal tumor of the CNS, often has many bizarre and atypical large cells. However, these cells possess cytoplasmic processes, resulting in a fibrillary appearance in the background, which are positive for GFAP, and are negative for histiocytic markers. Pleomorphic xanthoastrocytoma is a prototype of tumors with pleomorphic large cells; but spindle cells, lipidized cells, and eosinophilic granular bodies are present, in addition to large bizarre cells. These tumors can be differentiated from histiocytic sarcoma by positivity for GFAP and synaptophysin, and negativity for histiocytic markers. Anaplastic large cell lymphoma may be histologically indistinguishable from histiocytic sarcoma, due to high cellularity and significant nuclear atypia with occasional large bizarre cells. Anaplastic large cell lymphomas, however, are positive for CD30, but negative for histiocytic markers present in histiocytic sarcoma [1,9].
Treatment strategies for histiocytic sarcoma include surgical resection, steroid treatment, chemotherapy, and radiation. Although most tumors are unresectable due to location and number, a total excision, if feasible, should be considered since it may provide a better prognosis, with some patients surviving over 1 year from a diagnosis after complete resection [4,10].
Steroids may relieve the symptoms temporarily by reducing peritumoral vasogenic edema and oncolytic effect. However, steroid treatment should be avoided before diagnosis, as the oncolytic effects of steroids may interfere with accurate diagnosis.
The permeability of the blood-brain barrier (BBB) should be considered prior to prescribing chemotherapy. A high dose of MTX and Ara-C, which can easily penetrate the BBB, are the main agents used in the treatment for primary CNS lymphoma, which improve the overall survival. Both of these agents, however, were ineffective in our patient. Whole-brain irradiation may improve the responses to chemotherapy, albeit the rate of neurotoxicity is high.

Conflict of interest relevant to this article was not reported.

Fig. 1.
Brain (A, B) and spinal (C, D) magnetic resonance imaging (MRI) of the patient. (A) Brain FLAIR MRI showing high signal intensity in the left periventricular and deep white matter of the left parietal lobe. (B) T1-weighted axial enhancement of the brain, showing subtle enhancement of the lesion. (C) Sagittal T2-weighted spinal MRI, showing diffusely increased signal intensity lesion with mild cord enlargement in the lower level of C3 through the upper level of T5. (D) Sagittal T1-weighted MRI, showing patchy enhancement of the spinal cord.
crt-2013-163f1.gif
Fig. 2.
Cytologic and histologic features of the first cerebrospinal fluid (CSF) aspiration and biopsy of left parieto-occipital lesion. (A) Central nervous system smear, showing a few large cells with abundant cytoplasm and large nuclei (Giemsa staining, ×400). (B) The large cells in the solid sheet from the biopsy were similar to the cells in the CSF smear. Vessels are cuffed by mature lymphocytes (H&E staining, ×40). (C) A few bizarre cells, larger than the adjacent cells, were observed (H&E staining, ×200). (D) The cells, including the bizarre cells, were positive for CD68, consistent with histiocytes (×400).
crt-2013-163f2.gif
Fig. 3.
Histologic features of left parieto-occipital lesion from the second biopsy. (A) Large cells were arranged in a solid sheet, with a few intermixed larger bizarre cells, similar to findings in the first biopsy specimen. The nuclei of the background cells showed slight pleomorphism and coarse chromatin with no or small nucleoli. The cytoplasm was eosinophilic and cell membranes were not well-defined (H&E staining, ×400). (B-D) The cells were positive for CD68 (B) and CD163 (C), but negative for glial fibrillary acidic protein (D), consistent with histiocytic differentiation (×200).
crt-2013-163f3.gif
Table 1.
Summary of previously reported patients with primary CNS histiocytic sarcoma
Reference Age/Gender Site Numbers Size (cm)a) Treatment Clinical outcome
Gill-Samra et al. [2] 38 yr/F Posterior temporal lobe Solitary 5 Surgery+WBRT+ Chemotherapy (temozolomide) Died 3 weeks after the first cycle of temozolomide
Toshkezi et al. [3] 71 yr/F Intramedullary lesion (Tll-12), leptomeninges Solitary 2.5 Surgery+XRT Died 5 months after diagnosis
Bell et al. [4] 62 yr/F Posterior fossa Solitary ND Surgery Remains well 24 months after surgery
Bell et al. [4] 34 yr/M Frontal lobe Solitary 2 Surgery Remains well 10 months after surgery
Devic et al. [5] 43 yr/F Corpus callosum, Middle cerebellar peduncle, periventricular white matter, spinal cord Multiple ND Chemotherapy (steroid, vinblastine, cladribine) Died 10 months after diagnosis
Wang et al. [6] 55 yr/F Periventricular white matter Multiple ND Surgery+XRT+WBRT Died 4 months after diagnosis
Torres et al. [7] 20 mo/M Leptomeninges Solitary ND Chemotherapy (cyclophosphamide, idarubicin, vincristine, dexamethasone, intrathecal MTX, and Ara-C) 3 Months after onset of treatment
Cheuk et al. [8] 69 yr/F Parietal lobe Solitary 1.5 Surgery+WBRT+chemotherapy Died 8 months after therapy
Cheuk et al. [8] 43 yr/M Spinal cord Solitary 1.7 Surgery+XRT+chemotherapy Remains alive after 5 months
Cheuk et al. [8] 11 yr/M Cerebellum, occipital cortex, frontal lobe Multiple 0.7-1 Surgery Died 4 months after surgery
Sun et al. [9] 13 yr/M Occipital lobe and meninges ND ND Surgery 7 Months after onset of symptoms
Cao et al. [10] 53 yr/F Cavernous sinus, relapsed to mediastinum Solitary 3.1 Surgery+XRT Died of metastasis after 3.5 years
Almefty et al. [11] 16 yr/M Posterior parietal lobe Solitary 4.4 Surgery+XRT Died 4 months after presentation
Wu et al. [12] 50 yr/M Parieto-occipital area Solitary 1.7 Surgery+XRT Remains well 7 months after surgery
Laviv et al. [13] 58 yr/M Bifrontal lobe Solitary 6.5 Surgery Died 4 months after surgeryb)
Gomi et al. [14] 17 mo/F Cerebellum, Spinal dissemination (intradural lesion, below 10th thoracic vertebral level) Solitary 4.7 Partial resection+chemotherapy (carboplatin, procarbazine, etoposide, cisplatin, vincristine, and cyclophosphamide) Remains well 16 months after surgery with disease

CNS, central nervous system; F, female; WBRT, whole brain radiotherapy; XRT, radiotherapy; ND, no data; M, male; MTX, methotrexate.

a) Longest dimension,

b) Died from ventricular tachycardia, not by cancer.

  • 1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
  • 2. Gill-Samra S, Ng T, Dexter M, Wong M, Nahar N, Allsopp K, et al. Histiocytic sarcoma of the brain. J Clin Neurosci. 2012;19:1456–8. ArticlePubMed
  • 3. Toshkezi G, Edalat F, O'Hara C, Delalle I, Chin LS. Primary intramedullary histiocytic sarcoma. World Neurosurg. 2010;74:523–7. ArticlePubMed
  • 4. Bell SL, Hanzely Z, Alakandy LM, Jackson R, Stewart W. Primary meningeal histiocytic sarcoma: a report of two unusual cases. Neuropathol Appl Neurobiol. 2012;38:111–4. ArticlePubMed
  • 5. Devic P, Androdias-Condemine G, Streichenberger N, Berger F, Honnorat J, Broussolle E, et al. Histiocytic sarcoma of the central nervous system: a challenging diagnosis. QJM. 2012;105:77–9. ArticlePubMed
  • 6. Wang J, Li T, Chen H, Liu Q. A case of primary central nervous system histiocytic sarcoma. Clin Neurol Neurosurg. 2012;114:1074–6. ArticlePubMed
  • 7. Torres CF, Korones DN, Powers JM, Vadasz AG. Primary leptomeningeal histiocytic lymphoma in a young child. Med Pediatr Oncol. 1996;27:547–50. ArticlePubMed
  • 8. Cheuk W, Walford N, Lou J, Lee AK, Fung CF, Au KH, et al. Primary histiocytic lymphoma of the central nervous system: a neoplasm frequently overshadowed by a prominent inflammatory component. Am J Surg Pathol. 2001;25:1372–9. ArticlePubMed
  • 9. Sun W, Nordberg ML, Fowler MR. Histiocytic sarcoma involving the central nervous system: clinical, immunohistochemical, and molecular genetic studies of a case with review of the literature. Am J Surg Pathol. 2003;27:258–65. ArticlePubMed
  • 10. Cao M, Eshoa C, Schultz C, Black J, Zu Y, Chang CC. Primary central nervous system histiocytic sarcoma with relapse to mediastinum: a case report and review of the literature. Arch Pathol Lab Med. 2007;131:301–5. ArticlePubMedPDF
  • 11. Almefty RO, Tyree TL, Fusco DJ, Coons SW, Nakaji P. Primary histiocytic sarcoma of the brain mimicking cerebral abscess. J Neurosurg Pediatr. 2013;12:251–7. ArticlePubMed
  • 12. Wu W, Tanrivermis Sayit A, Vinters HV, Pope W, Mirsadraei L, Said J. Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. Hum Pathol. 2013;44:1177–83. ArticlePubMed
  • 13. Laviv Y, Zagzag D, Fichman-Horn S, Michowitz S. Primary central nervous system histiocytic sarcoma. Brain Tumor Pathol. 2013;30:192–5. ArticlePubMed
  • 14. Gomi K, Tanaka M, Yoshida M, Ito S, Sonoda M, Iwasaki F, et al. Primary cerebellar histiocytic sarcoma in a 17-month-old girl. J Neurosurg Pediatr. 2012;10:126–9. ArticlePubMed
  • 15. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review
      Luyi Zhang, Gang Zhang, Han Zheng, Bin Jiang, Yongzhi Ju, Qianqian Duan, Lu An, Hangyu Shi
      Brain Tumor Pathology.2024; 41(1): 18.     CrossRef
    • Primary Histiocytic Sarcoma of the Breast: A Case Report and Review of the Literature
      Hind Althomali, Haneen Al-Maghrabi, Nora Trabulsi, Jaudah Al-Maghrabi
      Cureus.2024;[Epub]     CrossRef
    • Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results
      Ryan Cecchi, Doré Guptil, Nicholas Haslett, Alexandra Hristov, Jacob R Bledsoe, Harrison Tsai, John DeWitt, Sean P Ferris
      Journal of Neuropathology & Experimental Neurology.2024; 83(10): 882.     CrossRef
    • Primary intracranial histiocytic sarcomas: a report of six cases and a pooled analysis of individual patient data
      Pengcheng Zuo, Mingxin Zhang, Wenhao Wu, Yu Wang, Tian Li, Tao Sun, YuJin Wang, Zhen Wu, Junting Zhang, Liwei Zhang
      Journal of Cancer Research and Clinical Oncology.2023; 149(13): 12071.     CrossRef
    • A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma
      David S Rogawski, Jeffrey J Nirschl, Jamie McDonald, Esther Nie, Nicholas U Schwartz, Hannes Vogel, Brian J Scott, Carl A Gold, Lucas B Kipp
      Multiple Sclerosis Journal.2022; 28(10): 1651.     CrossRef
    • New onset headache caused by histiocytic sarcoma of the spinal cord and leptomeninges: a case report
      Matthew Silsby, Winny Varikatt, Steve Vucic, Parvathi Menon
      BMJ Neurology Open.2021; 3(1): e000147.     CrossRef
    • Clinical Reasoning: A 42-Year-Old Woman With Mysterious Monocytic Meningitis
      Meghan E. Nothem, Ryan M. Lee, Jonathan M. Katz, Paul A. Bergl, Ahmed Z. Obeidat
      Neurology.2021; 97(9): 449.     CrossRef
    • Primary histiocytic sarcoma in the brain with renal metastasis causing internal ophthalmoparesis and external ophthalmoplegia in a Maine Coon cat
      Susana Monteiro, Katherine Hughes, Marie-Aude Genain, Lisa Alves
      Journal of Feline Medicine and Surgery Open Reports.2021;[Epub]     CrossRef
    • Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs
      Izumi Toyoda, William Vernau, Beverly K. Sturges, Karen M. Vernau, John Rossmeisl, Kurt Zimmerman, Chelsea M. Crowe, Kevin Woolard, Michelle Giuffrida, Robert J. Higgins, Peter J. Dickinson
      Journal of Veterinary Internal Medicine.2020; 34(2): 828.     CrossRef
    • Nonepithelial Tumors of the Larynx: Single-Institution 13-Year Review with Radiologic-Pathologic Correlation
      Andrew C. Ong, Eric H. Huh, Anna J. Moreland, Lisa M. Rooper, Nafi Aygun, Lee M. Akst, Simon R. Best, Majid A. Khan
      RadioGraphics.2020; 40(7): 2011.     CrossRef
    • Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review
      Jackson M. May, Mark R. Waddle, Daniel H. Miller, William C. Stross, Tasneem A. Kaleem, Byron C. May, Robert C. Miller, Liuyan Jiang, Gerald W. Strong, Daniel M. Trifiletti, Kaisorn L. Chaichana, Ronald Reimer, Han W. Tun, Jennifer L. Peterson
      Radiation Oncology.2018;[Epub]     CrossRef
    • Primary central nervous system histiocytic sarcoma
      Shuang Ma, Michael Schild, Diana Tran, Xuefeng Zhang, Wan-Lin Zhang, Shuai Shen, Hong-Tao Xu, Lian-He Yang, Endi Wang
      Medicine.2018; 97(26): e11271.     CrossRef
    • Case of primary central nervous system histiocytic sarcoma with prominent proliferation of histiocytic cells between the trabeculae of reactive glial cells
      Emiko Takahashi, Ayako Sakakibara, Toyonori Tsuzuki, Shigeo Nakamura
      Neuropathology.2018; 38(6): 609.     CrossRef
    • Primary histiocytic sarcoma presenting as diffuse leptomeningeal disease: Case description and review of the literature
      Magda Zanelli, Moira Ragazzi, Giovanni Marchetti, Alessandra Bisagni, Massimo Principi, Daniela Fanni, Elisabetta Froio, Silvia Serra, Eleonora Zanetti, Loredana De Marco, Felice Giangaspero, Stefano Ascani
      Neuropathology.2017; 37(6): 517.     CrossRef
    • Pediatric intracerebral histiocytic sarcoma with rhabdoid features: Case report and literature review
      Young Hye Kim, Gie‐Taek Yie, Na Rae Kim, In‐Sang Jeon, Hyun Yee Cho, Jae Yeon Seok, Eung Yeop Kim, Kyu Chan Lee
      Neuropathology.2017; 37(6): 560.     CrossRef
    • Looking for a Rarity: Histiocytic Sarcoma
      Joana de Castro Rocha, Isabel Paiva, Ana Rita Cruz
      Journal of Cancer Therapy.2016; 07(02): 79.     CrossRef
    • A Case of Histiocytic Sarcoma Arising in Head and Neck Region with Rhabdoid Differentiation
      Jeong Marn Kim, Yun Seok Oh, Dong Wook Lee
      Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2016; 59(9): 672.     CrossRef
    • A 43‐Year‐Old Female with Multifocal Cerebral Lesions
      Marieke B.B. Nieuwenhuis, Sandra M.A. van der Salm, Joost J.C. Verhoeff, Anneke J. van der Kooi, Ivana Slavujecvic‐Letic, Steven T. Pals, Josephine M.I. Vos
      Brain Pathology.2015; 25(3): 371.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Primary Histiocytic Sarcoma of the Central Nervous System
      Cancer Res Treat. 2015;47(2):322-328.   Published online August 29, 2014
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    Primary Histiocytic Sarcoma of the Central Nervous System
    Image Image Image
    Fig. 1. Brain (A, B) and spinal (C, D) magnetic resonance imaging (MRI) of the patient. (A) Brain FLAIR MRI showing high signal intensity in the left periventricular and deep white matter of the left parietal lobe. (B) T1-weighted axial enhancement of the brain, showing subtle enhancement of the lesion. (C) Sagittal T2-weighted spinal MRI, showing diffusely increased signal intensity lesion with mild cord enlargement in the lower level of C3 through the upper level of T5. (D) Sagittal T1-weighted MRI, showing patchy enhancement of the spinal cord.
    Fig. 2. Cytologic and histologic features of the first cerebrospinal fluid (CSF) aspiration and biopsy of left parieto-occipital lesion. (A) Central nervous system smear, showing a few large cells with abundant cytoplasm and large nuclei (Giemsa staining, ×400). (B) The large cells in the solid sheet from the biopsy were similar to the cells in the CSF smear. Vessels are cuffed by mature lymphocytes (H&E staining, ×40). (C) A few bizarre cells, larger than the adjacent cells, were observed (H&E staining, ×200). (D) The cells, including the bizarre cells, were positive for CD68, consistent with histiocytes (×400).
    Fig. 3. Histologic features of left parieto-occipital lesion from the second biopsy. (A) Large cells were arranged in a solid sheet, with a few intermixed larger bizarre cells, similar to findings in the first biopsy specimen. The nuclei of the background cells showed slight pleomorphism and coarse chromatin with no or small nucleoli. The cytoplasm was eosinophilic and cell membranes were not well-defined (H&E staining, ×400). (B-D) The cells were positive for CD68 (B) and CD163 (C), but negative for glial fibrillary acidic protein (D), consistent with histiocytic differentiation (×200).
    Primary Histiocytic Sarcoma of the Central Nervous System
    Reference Age/Gender Site Numbers Size (cm)a) Treatment Clinical outcome
    Gill-Samra et al. [2] 38 yr/F Posterior temporal lobe Solitary 5 Surgery+WBRT+ Chemotherapy (temozolomide) Died 3 weeks after the first cycle of temozolomide
    Toshkezi et al. [3] 71 yr/F Intramedullary lesion (Tll-12), leptomeninges Solitary 2.5 Surgery+XRT Died 5 months after diagnosis
    Bell et al. [4] 62 yr/F Posterior fossa Solitary ND Surgery Remains well 24 months after surgery
    Bell et al. [4] 34 yr/M Frontal lobe Solitary 2 Surgery Remains well 10 months after surgery
    Devic et al. [5] 43 yr/F Corpus callosum, Middle cerebellar peduncle, periventricular white matter, spinal cord Multiple ND Chemotherapy (steroid, vinblastine, cladribine) Died 10 months after diagnosis
    Wang et al. [6] 55 yr/F Periventricular white matter Multiple ND Surgery+XRT+WBRT Died 4 months after diagnosis
    Torres et al. [7] 20 mo/M Leptomeninges Solitary ND Chemotherapy (cyclophosphamide, idarubicin, vincristine, dexamethasone, intrathecal MTX, and Ara-C) 3 Months after onset of treatment
    Cheuk et al. [8] 69 yr/F Parietal lobe Solitary 1.5 Surgery+WBRT+chemotherapy Died 8 months after therapy
    Cheuk et al. [8] 43 yr/M Spinal cord Solitary 1.7 Surgery+XRT+chemotherapy Remains alive after 5 months
    Cheuk et al. [8] 11 yr/M Cerebellum, occipital cortex, frontal lobe Multiple 0.7-1 Surgery Died 4 months after surgery
    Sun et al. [9] 13 yr/M Occipital lobe and meninges ND ND Surgery 7 Months after onset of symptoms
    Cao et al. [10] 53 yr/F Cavernous sinus, relapsed to mediastinum Solitary 3.1 Surgery+XRT Died of metastasis after 3.5 years
    Almefty et al. [11] 16 yr/M Posterior parietal lobe Solitary 4.4 Surgery+XRT Died 4 months after presentation
    Wu et al. [12] 50 yr/M Parieto-occipital area Solitary 1.7 Surgery+XRT Remains well 7 months after surgery
    Laviv et al. [13] 58 yr/M Bifrontal lobe Solitary 6.5 Surgery Died 4 months after surgeryb)
    Gomi et al. [14] 17 mo/F Cerebellum, Spinal dissemination (intradural lesion, below 10th thoracic vertebral level) Solitary 4.7 Partial resection+chemotherapy (carboplatin, procarbazine, etoposide, cisplatin, vincristine, and cyclophosphamide) Remains well 16 months after surgery with disease
    Table 1. Summary of previously reported patients with primary CNS histiocytic sarcoma

    CNS, central nervous system; F, female; WBRT, whole brain radiotherapy; XRT, radiotherapy; ND, no data; M, male; MTX, methotrexate.

    Longest dimension,

    Died from ventricular tachycardia, not by cancer.


    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP